Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus (NCT07400952)

🧪 Interventions in This Study

• GLK-221 Ophthalmic Solution (DRUG)
• Placebo Ophthalmic Solution (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Glaukos Clinical Study Site — Westerville, Ohio

📞 Contact the Study Coordinator

Phone: (949) 739-8749

Email: ClinicalResearch@Glaukos.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Keratoconus

• Initial Correction Keratoconus — Chicago, Illinois
• McNeel Eye Center Corneal Crosslinking Study — Boise, Idaho
• Assessing Patient Engagement in Keratoconus Clinical Research — San Francisco, California
• Outcomes of CTAK Surgery — Palo Alto, California
• A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients — Boston, Massachusetts
• OCT in Diagnosis of Irregular Corneas — Portland, Oregon

Explore by condition: All Keratoconus clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.